An Evaluation of a Dynamic Web-Based Visualization of Community Immunity

March 4, 2021 updated by: Laval University
This study is a PhD project conducted by Ms. Hina Hakim, supervised by Dr. Holly O. Witteman, PhD, and co-supervised Dr. Daniel Reinharz, professors and researchers at the Faculty of Medicine at Laval University. The purpose of this study is to evaluate the effects of visualization conveying the concept of community immunity or herd immunity on risk perception (towards individual, family, community and vulnerable people in communities) (primary outcome) and on emotions, attitudes, knowledge, and behavioural intentions (secondary outcomes).

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Visualization is a powerful communication mechanism that uses pre-attentive processing to communicate large amounts of information rapidly in understandable and compelling ways (Healey and Enns 2012). A systematic review demonstrates that there are some interventions available for conveying the concept of community immunity, and very few evaluate interventions for their effects on vaccine intentions and uptake as well as their precursors, such as knowledge, attitudes, knowledge and none on emotions (Hakim et al. 2018).

The purpose of this study is to evaluate the effects of visualization conveying the concept of community immunity on risk perception (to individual, family, community and vulnerable people in communities) (primary outcome) and on emotions, attitudes, knowledge, and behavioural intentions (secondary outcomes).

Study Type

Interventional

Enrollment (Anticipated)

5440

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Members of the general population in Canada
  • At least 18 years old
  • Able to provide free and informed consent
  • Able to read and understand French or English
  • Able to use a computer

Exclusion Criteria:

- No internet access

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: controlgeneric
No intervention provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English and French.
No Intervention: controlmeasles
No intervention provided. Participant answers outcome questions about measles. English and French.
No Intervention: controlpertussis
No intervention provided. Participant answers outcome questions about pertussis. English and French.
No Intervention: controlflu
No intervention provided. Participant answers outcome questions about flu. English and French.
Experimental: herdimmgeneric
Web-based application (main intervention) provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English and French.
Behavioral: herdimm
In this visualization participants can build their own avatar representing themselves and 8 other avatars representing people around them, like their family or coworkers. Our visualization then uses these avatars in a brief narrated video explaining how herd immunity works.
Experimental: herdimmmeasles
Web-based application (main intervention) provided. Participant answers outcome questions about measles. English and French.
Behavioral: herdimm
In this visualization participants can build their own avatar representing themselves and 8 other avatars representing people around them, like their family or coworkers. Our visualization then uses these avatars in a brief narrated video explaining how herd immunity works.
Experimental: herdimmpertussis
Web-based application (main intervention) provided. Participant answers outcome questions about pertussis. English and French.
Behavioral: herdimm
In this visualization participants can build their own avatar representing themselves and 8 other avatars representing people around them, like their family or coworkers. Our visualization then uses these avatars in a brief narrated video explaining how herd immunity works.
Experimental: herdimmflu
Web-based application (main intervention) provided. Participant answers outcome questions about flu. English and French.
Behavioral: herdimm
In this visualization participants can build their own avatar representing themselves and 8 other avatars representing people around them, like their family or coworkers. Our visualization then uses these avatars in a brief narrated video explaining how herd immunity works.
Active Comparator: robertkochgeneric
Web-based application (comparator) provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English only.
Behavioral: robertkochgeneric
A web-based application showing how herd immunity works in general: http://rocs.hu-berlin.de/D3/herd/
Active Comparator: sbsnewsgeneric
Video (comparator) provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English only.
Behavioral: sbsnewsgeneric
A video showing how herd immunity works in general: https://www.sbs.com.au/news/two-sydney-babies-too-young-to-be-vaccinated-infected-with-measles
Active Comparator: guardianmeasles
Video (comparator) provided. Participant answers outcome questions about measles. English only.
Behavioral: guardianmeasles
A screen capture of an interactive visualization: https://www.theguardian.com/society/ng-interactive/2015/feb/05/-sp-watch-how-measles-outbreak-spreads-when-kids-get-vaccinated
Active Comparator: theotheredmundmeasles
Video (comparator) provided. Participant answers outcome questions about measles. English only.
Behavioral: theotheredmundmeasles
A gif showing measles spreading through populations with differing levels of vaccine coverage: https://imgur.com/gallery/8M7q8#J7LANQ4
Active Comparator: publichealthagencycanadaflu
Video (comparator) provided. Participant answers outcome questions about flu. English and French.
Behavioral: publichealthagencycanadaflu
A video showing how herd immunity works in the context of influenza: https://www.canada.ca/fr/sante-publique/services/video/la-grippe-n-en-passez-pas-les-maux.html

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Risk perception
Time Frame: immediately after intervention or control
6 ad hoc questions assessing risk perception
immediately after intervention or control

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
emotions, attitudes, knowledge, and behavioural intentions
Time Frame: immediately after intervention or control
ad hoc questions and 5C scale (Betsch et al.)
immediately after intervention or control

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Laval University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

March 1, 2021

Primary Completion (Anticipated)

May 1, 2021

Study Completion (Anticipated)

December 1, 2021

Study Registration Dates

First Submitted

March 4, 2021

First Submitted That Met QC Criteria

March 4, 2021

First Posted (Actual)

March 9, 2021

Study Record Updates

Last Update Posted (Actual)

March 9, 2021

Last Update Submitted That Met QC Criteria

March 4, 2021

Last Verified

March 1, 2021

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • herdimm

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Anonymized data (answers to questions in the survey including socio-demographic information) will be deposited in a public repository (Dataverse de l'Université Laval (Laval University)) which will allow data sharing with the scientific community. No information that would allow anyone to identify a person will be deposited in this public repository. Study protocol and statistical analysis plan have been deposited in Open Science Framework.

IPD Sharing Time Frame

As soon as possible upon completion of the study and posting of a preprint with results.

IPD Sharing Access Criteria

Freely available.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Understanding of Community Immunity as a Concept

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe